IJPSR (2023), Volume 14, Issue 5



(Research Article)



Received on 05 September 2022; received in revised form, 29 October 2022; accepted 24 April 2023; published 01 May 2023

INFECTIONS ASSOCIATED WITH BIOLOGIC THERAPY: A CLINICAL META-ANALYSIS **STUDY**

INTERNATIONAL JOURNAL OF UTICAL

> AND SEARCH

SCIENCES

Anjali Nayak¹, Rahul Semwal², Pritish Kumar Varadwaj¹ and Imlimaong Aier^{*1}

Department of Bioinformatics and Applied Sciences¹, Indian Institute of Information Technology-Allahabad, Prayagraj - 211015, Uttar Pradesh, India.

Department of Computer Science and Engineering², Indian Institute of Information Technology-Nagpur, Nagpur - 441108, Maharashtra, India.

Keywords:

Biologics, Tuberculosis, Inflammatory disease, Meta-analysis

Correspondence to Author: Imlimaong Aier

Post-Doctoral Fellow, Department of Bioinformatics and Applied Sciences, Indian Institute of Information Technology-Allahabad, Prayagraj - 211015, Uttar Pradesh, India.

E-mail: imliaier@gmail.com

ABSTRACT: With the popularity of biologics, treatment for several inflammatory diseases has improved significantly. Biologics are a group of drugs obtained from biological sources that primarily function by suppressing part of the host immune system. However, this process comes at a cost, as it has been reported that the use of biologics carry a major risk in the form of tuberculosis. To verify this claim, a meta-analysis of biologic therapy vs. placebo therapy was designed to test biologics of different inflammatory diseases and check for tuberculosis as their side effect. This test included psoriasis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. It was found that biologics used in treating these diseases were mainly responsible for the spread of tuberculosis as a side effect. By mining different databases for literature mentioning biologics that qualify clinical trials and checking for heterogeneity for each study, primary measures were tested for each disease to determine the spread of tuberculosis when treated with these compounds. Meta-analyses were conducted for the study of each disease separately. It was found that for ankylosing spondylitis, Crohn's disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis the null hypothesis Ho:µ=0 can be rejected. All primary measures showed statistically significant results for the spread of tuberculosis infection. Therefore, it can be concluded that biologics used to treat these inflammatory diseases may be spreading infections in the form of tuberculosis.

INTRODUCTION: Biologics are a group of drugs developed in the early 1980's that are obtained from biological sources which primarily function by suppressing part of the host immune system¹. Biologic compounds are heavily used to diagnose, prevent, and treat human diseases and inflammatory conditions.



Biologics vary from traditional pharmaceutical drugs in various aspects, such size, as heterogeneity, characterization Thus. and biologics development is costly and difficult due to engineering intensive and manufacturing requirements.

However, biologics remain effective and are the preferred therapeutic mode when treating severe diseases. One of the most successful and growing classes of biologics is monoclonal antibodies, proteins secreted by white blood cells that protect the body from foreign invaders. Whenever the pathogens express antigens, antibody immediately triggers an immune response which helps the body ward off the invader. Similar to antibodies, therapeutic monoclonal antibodies are produced from living organisms and engineered to work against a particular antigen concerning the disease³. Due to the precision during engineering, therapeutic monoclonal antibodies often produce results similar to the human immune response when combating antigens. Due to the growing use of new immune-modulating therapies. comprehending infectious complications the associated with it is even more important, mainly the risk of tuberculosis and herpes zoster ^{4, 5}. In this study, the aim was to identify the association of these agents with different infections through metaanalysis. Many immune-modulating drugs are still spreading infections in patients and are untested. Thus, the main objective was to target biologics that could cause tuberculosis as the side effect for different diseases. For this study, literature published between 2009 and 2021 were selected from PUBMED, EMBASE and Cochrane central library.

MATERIALS AND METHODS:

Extraction of Data. Selection and Characteristics of Studies: The data were collected from clinical trial organization website (clinicaltrial.org) with the help of specific keywords "ankylosing spondylitis", "Crohn's disease", "adalimumab", "psoriasis", "infliximab", "etanercept", "ulcerative colitis", "rheumatoid arthritis", "psoriatic arthritis" containing placebocontrolled study. The titles and abstract of each study for each disease were inspected for the criteria mentioned above. The selection criteria based on which the studies were included were that the selected studies should be completed, the involved treatment should be the biologics causing

tuberculosis as side effect compared to the placebo, and that the patients included in the studies should have the diseases selected for this study. Exclusion criteria was set based on certain conditions, such as the patient should not have active tuberculosis. hepatitis B or hepatitis C, or have previous anti-TNF therapy. The patient should not have any history of demyelinating disease, multiple sclerosis or cancer. After applying these criteria the number of studies selected were ⁸ in ankylosing spondylitis, ⁶ in Crohn's disease, ⁷ in psoriasis, ⁸ in psoriatic arthritis, 5 in rheumatoid arthritis, ⁶ in ulcerative colitis. The baseline characteristics of patients were studied. Total 4392 patients of ankylosing spondylitis out of 8 studies ^{6, 7, 8, 9, 10, 11, 12, 13}, 2992 patients of Crohn's disease out of 6 studies ^{14, 15, 16,} ^{17, 18}, 2648 patients of Psoriasis out of 7 studies ^{19, 20, 21, 22, 23, 24, 25}, 3046 patients of Psoriatic Arthritis out of 8 studies ^{26, 27, 28, 29}, ^{30, 31, 32, 33}, 1176 patients of Rheumatoid Arthritis out of 5 studies ^{34, 35, 36, 37,} ³⁸, 1487 patients of Ulcerative Colitis out of 6 studies ^{39, 40, 41, 42, 43, 44}. The heterogeneity of studies was checked using χ^2 and I2 index statistics. Funnel plot was used for the efficacy measure of publication bias.

The required data were extracted from various studies and divided into two groups; experiment group (biological therapy) and the control group (placebo therapy) for meta-analysis; the baseline characteristics are tabulated in **Table 1**. The data extracted were the name of the study, number of patients, year, age, study design, and biologics level. The primary endpoint measures were that the biological therapy should favor experiments that indicate the possibility of tuberculosis as a side effect in these diseases' biologics.

 TABLE 1: BASELINE CHARACTERISTICS OF PATIENTS WITH ANKYLOSING SPONDYLITIS, CROHN'S

 DISEASE, PSORIASIS, PSORIATIC ARTHRITIS, RHEUMATOID ARTHRITIS AND ULCERATIVE COLITIS

Disease	Study	No. of	Year	Age (Years)	Study design	Therapy	Dosage	Intervention
		patients				Period	Regimen	
Ankylosing	Abbott	315	2011	42.2 (11.57)	Double blind	12 weeks	40 mg/week	Adalimumab
spondylitis	Wyeth	566	2012	40.76 (11.86)	Double blind	16 weeks	50 mg/week	Etanercept
	Centocor	356	2013	39.3 (12.06)	Double blind	24 weeks	100 mg/4	Golimumab
	Inc.						weeks	
	Pfizer	1715	2015	43.9 (12.9)	Cohort	52 weeks	50mg/week	Etanercept
	Novartis	60	2015	42.8 (9.88)	Double blind	28 weeks	0.1mg/kg/3 weeks	AIN457
	AbbVie	789	2013	49.3 (13.3)	Case-only	13 month		Humira
	Celgene	490	2019	44.7 (12.18)	Double blind	24 weeks	30 mg /week	Apremilast
	Corp.							
	Merck &	101	2019	44.4 (12.9)	Open label	12	50 mg/month	GLM
	Sharp &					months	-	

International Journal of Pharmaceutical Sciences and Research

$ \begin{array}{c crohn's brack Phi and Pharma brack Phi and Phi$		D.I.							
		Dohme							
disease UCB 5.39 2011 37.67 (12.19) Double blind 26 weeks 400mg/2 CertolizumabPegol Pharma UCB 40 2015 31.7 (9.7) Open label 6 weeks 400mg/5 CertolizumabPegol Pharma Abbott 188 2011 13.6 (2.49) Double blind 52 weeks 400mg/5 CertolizumabPegol Janssen 297 2013 36.3 (12.66) Double blind 52 weeks	Crohn's		235	2009	40.9 (12.8)	Double blind	12 weeks	10 sessions	Adacolumn
UCB Pharma40201531.7 (9.7) 31.7 (9.7)Open label open label6 weeks weeks400mg(x) weeksCertoiizumabPegol weeksAbbort Jansen188201113.6 (2.49) 36.3 (12.96)Double blind Double blind22 weeksAddiimunah weeksPsoriasisWyeth1693201435.5 (11.7) 45.03 (11.85)Cohort24 weeksHumira EnarceptPsoriasisWyeth69201345.84 (11.57) 45.03 (11.85)Open label 912 weeks50 mg/week weeksEnarcept weeksPsoriasisWyeth69201345.84 (11.57) 45.03 (11.85)Open label 924 weeks50 mg/week weeksEnarcept dailyPsizer171201540.08 (13.96) 500Open label 922 weeks50 mg/week dailyEnarcept dailyPsizer171201540.08 (13.96) 500Open label 912 weeks30 mg twice dailyApremilast dailyCelgene844201646.6 (12.95)Double blind12 weeks50 mg/weekUsteinumab monthsPsizer170201252Double blind12 weeks90 mg/weekUsteinumab dailyPrizer170201252Double blind16 weeks60 mg on day dailyWyeth753200946.52 (11.40)Double blind12 weeks90 mg/weekCertoizumabPegol weekyUCB409201647.6 (11.4)Double blind10 mg/kg169 da	disease					Double blind	26 weeks	400mg/2	CertolizumabPegol
Pharma does it is it			10						a 11 15 1
Abbott 188 2011 3.6.3 (12.96) Double blind 200 weeks Psoriasis 297 2015 3.6.3 (12.96) Double blind 200 Smg/kg/k Adalimumab Psoriasis Wyeth 1693 2014 35.5 (11.7) Cohort 24 weeks Humira Psoriasis Wyeth 69 2013 45.83 (11.85) Open label 12 weeks Som givece Enancrept Abbott 147 2011 44.24 (12.82) Open label 12 weeks So mg/week Adalimumab Prizer 171 2015 40.08 (13.96) Open label 12 weeks 30 mg/week Adalimumab Celgene 844 2016 46.61 (12.95) Double blind 12 weeks 30 mg/week Ustancrept Bristol 170 2012 52 Double blind 12 weeks 90 mg/week Ustancrept Myers 53 2014 48.7 (10.97) Double blind 12 weeks 90 mg/week Ustancrept			40	2015	31.7 (9.7)	Open label	6 weeks		CertolizumabPegol
Abboti 188 2011 13.6 (2.49) Double blind 20 40 m_2/week 40 m_2/week 41 m_1/m_m Biotech 1001 3.6 (12.96) Double blind 20 5mg/kg/8 Weeks - Humin Psoriasis Wyeth 603 2014 35.5 (11.7) Cohort 24 weeks 50 mg/week Humin Abboti 147 2011 44.2 (18.2) Open label 12 weeks 50 mg/week Etanercept Abboti 147 2011 40.98 (13.90) Open label 22 weeks 80 mg/week Adalimumab Prizer 171 2015 40.98 (13.90) Open label 12 weeks 50 mg/week Adalimumab Abbvie 500 2014 40.0 (12.91) Double blind 16 weeks 30 mg rvice Adalimumab Myers 170 2012 52 Double blind 12 weeks 30 mg rvice Malimumab Myers 170 2012 52 Double blind 12 weeks 30 mg rvice <t< td=""><td>Filatilla</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>		Filatilla							
Jamsen Biotech AbbVie 297 2015 35.3 (12.96) Double blind 200 Smithy 8/8 weeks Infliximab Psoriasis Wyeth 1693 2014 35.5 (11.7) Cohort 12 weeks		Abbott	188	2011	13.6 (2.49)	Double blind	52 weeks		Adalimumab
AbbVie 1693 2014 35.5 (11.7) Cohor 24 weeks		Janssen	297	2015		Double blind		-	Infliximab
Psoriasis Wyeth 720 2010 45.03 (11.85) Open label 12 weeks 50 myweek S0 myweek Etaneccept weekly Wyeth 69 2013 45.84 (11.57) Open label 24 weeks 50 myweek Finneccept Abbott 147 2012 95 Open label 24 weeks 50 myweek Finneccept Pfizer 171 2015 49.08 (13.96) Open label 52 weeks 50 myweek Etaneccept AbbVie 500 2014 500 Prospective 12 - Adalimumab Celgene 844 2016 46.0 (12.95) Double blind 12 weeks 30 myweek Apremilast Celgene 753 2009 46.52 (11.40) Double blind 12 weeks 50 myweekly Etaneccept Bristol 170 2012 52 Double blind 169-729 Abatacept Myers Squibb 2016 50.4 (11.60) Double blind 10 mgg 5 years Apremilast						~ .			
Wyeth 69 2013 45.84 (11.57) Open label 24 weeks 50 mg/week Enarcept Abbott 147 2011 44.2 (12.82) Open label 12 weeks 50 mg/week Enarcept Pfizer 197 2012 96 Double blind 12 weeks 50 mg/week Enarcept AbbVie 500 2014 500 Prospective 12 - Adalimumab AbbVie 500 2014 500 Double blind 12 weeks 50 mg/week Apremilast Celgene 844 2016 46.0 (12.95) Double blind 12 weeks 50 mg/week Usekinumab Inc. minsiol 170 2012 52 Double blind 169-729 Abatacept Myers Novartis 42 2015 47.0 (10.2) Double blind 10 mg/kg 169 days AIN457 Gelgene 504 2016 50.4 (11.66) Double blind 10 mg/kg 48 weeks GerolizumabPegol	Dessiste								
	PSOIIasis	w yeth	720	2010	45.05 (11.85)	Open laber	12 weeks		Etanercept
Pfizer 197 2012 96 Double blind 12 weeks 15 mg twice (h) CP-690,550 (h) Pfizer 171 2015 49.08 (13.96) Open label 52 weeks 50 mg/week Einaercept AbbVie 500 2014 500 Double blind 16 weeks 50 mg/week Adalimumab Celgene 844 2016 46.0 (12.95) Double blind 12 weeks 50 mg weekly Einaercept Centocor 146 2013 48.7 (10.97) Double blind 12 weeks 50 mg/week Ustekinnmab Inc. 170 2012 52 Double blind 169-729 Abatacept Myers Squibb 170 2016 47.0 (10.2) Double blind 10 mg/kg 169 days AIN457 Pharma Celgene 504 2016 50.4 (11.66) Double blind 100 mg/kg 24 weeks CertolizumabPegol Invice weekly 119 days Alter 211 49.52 (11.87) Double blind 150 mg 24 weeks Secukinumab Intrine 606 20		Wyeth	69	2013	45.84 (11.57)	Open label	24 weeks		Etanercept
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $					44.2 (12.82)	•			
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		Pfizer	197	2012	96	Double blind	12 weeks		CP-690,550
AbbVie5002014500Prospective12Adalimumab months nothesCelgene844201646.0 (12.95)Double blind16 wceks30 mg twice dailyApremilast dailyWyeth753200946.52 (11.40)Double blind12 weeks90 mg/weekEtanerceptWyeth753200946.52 (11.40)Double blind12 weeks90 mg/weekUstekinumabInc.Bristol170201252Double blind169-729AbataceptMyersSquibb42201547.0 (10.2)Double blind10 mg/kg169 daysAIN457arthritisVorartis42201650.4 (11.6)Double blind10 mg/kg169 daysAIN457Psoriatic arthritisWorstis6062016552Double blind30 mg5 yearsApremilastVicce corp.6062016552Double blind160 mg 24 weeksSecukinumab24 weeksSecukinumabRheumatoi d arthritisAbbott6192011402Double blind120 weeks40 mg / weekAdalimumabMicro corp.50201554.9 (11.23)Double blind120 weeks50 mg one day 1, 5, 43CanakinumabInct.334201254.0 (13.15)Double blind12 weeks50 mg one day 1, 5, 43MrCB018424Mituitis93201427Double blind12 weeks50 mg one day 1, 5, 43MrP- <b< td=""><td></td><td>Dfizer</td><td>171</td><td>2015</td><td>40.08 (13.06)</td><td>Open label</td><td>52 weeks</td><td></td><td>Etanercent</td></b<>		Dfizer	171	2015	40.08 (13.06)	Open label	52 weeks		Etanercent
Psoriatic arthritis844201646.0 (12.95) 46.52 (11.40) Double blindDouble blind 12 weeks16 weeks daily 50 mg weeklyApremilast dailyPsoriatic arthritis170201252Double blind 48.7 (10.2)12 weeks90 mg/weekUstekinumabPsoriatic arthritis170201252Double blind 48.7 (10.2)10 mg/kg on day 12 and 22 and 22AbataceptPsoriatic arthritis409201647.6 (11.4) 49.6 (11.4)Double blind blind10 mg/kg on day 12 and 22 and 22 and 22 and 22169 days and 22 and 22 con day 1252CertolizumabPegol twice weeklyPsoriatic arthritis409201650.4 (11.66) 50.4 (11.66)Double blind blind10 mg/kg and 22 and 22 and 22 and 22 and 2248 weeks certolizumabPegol twice dailyCertolizumabPegol twice dailyNovartis d d arthritis6062016552 2016Double blind 160 mg and 2224 weeks and 22 and 22 and 2224 weeks and 22 and 22Secukinumab day 30 mg and 22Rheumatoi d arthritisAbbott619 334201246.9 (16.22) 46.9 (16.22)Double blind Double blind12 weeks and 22 and 22 bouble blind24 weeks and 22 and 22Adalimumab day 1, 15.43Rheumatoi d arthritisAbbott619 334201254.0 (13.15)Double blind and 2222 weeks and 2224 weeks and 22Certolizumab/a anab and 22 <tr< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr<>									
$ \begin{array}{c} \begin{array}{c} Corp. \\ Wyeth & 753 \\ Centocor & 146 \\ 2013 & 46.52 (11.40) \\ 12 weeks \\ 90 ng weekly \\ 90 ng week$		100,10	200	2011	2000	riospective			1100011100
			844	2016	46.0 (12.95)	Double blind	16 weeks		Apremilast
Centocor Inc. Bristol146201348.7 (10.97) 2012Double blind12 weeks90 ng/weekUstekinumabBristol Myers Squibb170201252Double blind169-729 daysAbataceptPsoriatic arthritisNovartis42201547.0 (10.2)Double blind10 mg/kg on day 1 and 22169 days and 22AIN457Psoriatic arthritisUCB Pharma409201647.6 (11.4)Double blind400mg twice weekly48 weeksCertolizumabPegol twice twice dailyCelgene Corp.504201650.4 (11.66)Double blind30 mg twice twice daily5 years twice dailyApremilast trace dailyNovartis d arthritis6062016552 2012Double blind 160 mg 201224 weeksSecukinumab dof 25 SC injectionsRheumatoi d arthritisAbbott 6196192011 2012402 40.52 (11.87)Double blind Double blind150 mg / week 30 mg once dailyAdaimumab daily 1.5.43Incyte Corp.50201554.9 (11.23)Double blind 22 weeks20 mg SC/ weekAdaimumab weekMitsubishi ranabe Pharma Corp.60201313.4 (3.10)Open label54 weeks5 mg/kg every 12 weekUlcerative colitis60201427Double blind8 weeks9 mg every dailyBudesonide-MMX dary 435+Methotrexate PharmaValeant Ph. ranabe Pharma <td< td=""><td></td><td></td><td>750</td><td>2000</td><td>46.52 (11.40)</td><td></td><td>10 1</td><td></td><td></td></td<>			750	2000	46.52 (11.40)		10 1		
Inc. Bristol Myers Squibb170201252Double blind days169-729 days-AbataceptPsoriatic arthritisNovartis42201547.0 (10.2)Double blind10 mg/kg and 21 and 22169 daysAIN457 and 22UCB Pharma409201647.6 (11.4)Double blind10 mg/kg and 22169 daysAIN457 and 22UCB Pharma409201650.4 (11.6)Double blind30 mg and 225 yearsApremilast dailyCelgene Corp.504201650.4 (11.66)Double blind30 mg and 245 yearsApremilast dailyNovartis company6062016552 and 2017Double blind150 mg and 24 weeks24 weeksSecukinumab and 25Rheumatoi d arthritisAbbott619 and 2012201246.9 (16.22) and 2012Double blind12 weeks40 mg / week dailyAdaimumab day 1, 15.43 day 1, 15.43 day 1, 15.43Incyte Corp. Tanabe Pharma Corp.50201554.9 (11.23)Double blind28 days50 mg once1NCB018424 dailyUlcerative collis600201313.4 (3.10)Open label12 weeks5 mg/kg every 12 weeksInfliximab every 12Ulcerative collisCentocor Inc.60201313.4 (3.10)Open label54 weeks5 mg/kg every 12Infliximab every 12Ulcerative collisCentocor Inc.60201313.4 (3.10)					· · · ·				
Bristol Myers Squibb170201252Double blind days169-729 daysAbataceptPsoriatic arthritisNovartis42201547.0 (10.2)Double blind10 mg/kg on day 1 and 22169 daysAIN457Psoriatic arthritisUCB Pharma409201647.6 (11.4)Double blind400mg twice48 weeksCertolizumabPegol twice weeklyCelgene Corp.504201650.4 (11.66)Double blind30 mg twice twice daily5 years twice dailyApremilastNovartis d arthritis6062016552Double blind 160 mg 21 K 2 SC injections150 mg 24 weeks24 weeks Secukinumab to 2 SC injections24 weeks twice dailySecukinumab day 1,15,43Rheumatoi d arthritisAbbott6192011402 2012Double blind 10 uble blind12 weeks600 mg on day 1,15,43Incyte Corp.50201554.9 (11.23)Double blind 22 weeks22 weeks40 mg SC/ weekAdalimumab weekAbbott334201254.0 (13.15)Double blind 22 weeks12 weeks100 mg twice dailyMP- d35+HethotrexateMitsubishi ranabe Pharma Corp.60201313.4 (3.10)Open label54 weeks5 mg/kg grey grey dailyInfliximab every 12 weeksUlcerative colitisValeant Ph. Int.Inc.201442.7 (12.8)Double blind8 weeks9 mg every grey grey <td< td=""><td></td><td></td><td>140</td><td>2015</td><td>40.7 (10.97)</td><td>Double blilld</td><td>12 weeks</td><td>90 mg/week</td><td>Ustekiituillab</td></td<>			140	2015	40.7 (10.97)	Double blilld	12 weeks	90 mg/week	Ustekiituillab
Squibb arthritisSquibb Novaris42201547.0 (10.2)Double blind10 mg/g on day 1 and 22 and 22169 daysAIN457UCB Pharma409201647.6 (11.4)Double blind400mg twice weekly48 weeksCertolizumabPegol twice dailyCelgene Corp.504201650.4 (11.60)Double blind30 mg twice daily5 yearsApremilast twice dailyNovaris company6062016552Double blind160 mg toice twice daily24 weeksSecukinumab IxeeksRheumatoi d arthritisAbbott619201149.52 (11.87) 49.52 (11.87)Double blind160 mg touble blind24 weeksSecukinumab taipetionsRheumatoi d arthritisAbbott6192011402 46.9 (16.22)Double blind12 weeks600 mg on day 1,15,43Incyte Corp.50201554.9 (11.23)Double blind28 days50 mg once twice dailyINCB018424 dailyAbbott334201254.0 (13.15)Double blind12 weeks40 mg SC/ weekAdalimumab weekUlcerative colitisCentocor Inc.60201313.4 (3.10)Open label54 weeks5 mg/kg every 12 weeksInfliximab every 12 weeksUlcerative colitisCentocor Inc.60201443.6 (13.6)Double blind8 weeks9 mg every day+3 EntocortBudesonide-MMX day+3Ulcerative totlint.Valean			170	2012	52	Double blind	169-729		Abatacept
Psoriatic arthritisNovartis42201547.0 (10.2) 47.0 (10.2)Double blind on day 1 and 22 and 22169 days on day 1 and 22 400mg twice169 days on day 1 and 22AIN457UCB Pharma409 Celgene Corp.201647.6 (11.4) 50.4 (11.66)Double blind Double blind400mg twice daily48 weeks weeklyCertolizumabPegol twice dailyNovartis Eli lilly& d arthritis606 Novartis201650.4 (11.66) 552Double blind Double blind160 mg 150 mg24 weeks secukinumab injectionsSecukinumab twice dailyRheumatoi d arthritisAbbott619 20112011 49.52 (11.87)Double blind Double blind150 mg 150 mg24 weeks 40 mg / weekAdalimumab day 1,15,43Rheumatoi d arthritisAbbott619 20112011 40.240.2 Double blindDouble blind 12 weeks500 mg onc 40 mg / weekAdalimumab day 1,15,43Incyte Corp.50 Tanabe Pharma Corp.201554.9 (11.23) 50Double blind22 weeks 40 mg SC/ adaily100 mg twice dailyMP- dailyUlcerative colitis60 Inc.201313.4 (3.10)Open label54 weeks500 mg twice every 12 weeksUlcerative colitis1nc.201443.6 (13.6)Double blind8 weeks9 mg every g everyBudesonide-MMX day+3 EntocortUlcerative colitis1nc.489201442.7 (12.8)Double blind8 weeks </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>days</td> <td></td> <td></td>							days		
arthritisUCB pharma409201647.6 (11.4)Double blind400mg and 22 and 22 weekly48 weeks weeklyCertolizumabPegol twice weeklyCelgene Corp.504201650.4 (11.66)Double blind30 mg twice daily5 yearsApremilast twice dailyNovartis Eli lilly& company6062016552 2017Double blind150 mg 160 mg24 weeksSecukinumab ItxekizumabRheumatoi d arthritisAbbott619 802011402 2012Double blind52 weeks 12 weeks40 mg / week 40 mg / weekAdalimumab Canakinumab day 1,15,43Incyte Corp.50 2015201554.9 (11.23) 54.9 (11.23)Double blind52 weeks 40 mg / weekAdalimumab day 1,15,43Incyte Corp.50 2018201254.0 (13.15) 70 uble blindDouble blind52 weeks40 mg SC/ dailyMitsubishi Tanabe Pharma Corp.93 70 and201427 2013Double blind12 weeks100 mg twice dailyUlcerative colitisCertocor Inc.60 2013201427 2013Double blind12 weeks100 mg twice dailyValeant Ph. In,Inc.410 Valeant Ph.201443.6 (13.6)Double blind8 weeks9 mg every g every 12 weeksValeant Ph. In,Inc.489 Valeant Ph.201442.7 (12.8)Double blind8 weeks9 mg every g everyBudesonide-MMX day+2 Asacol	D:		40	2015	47.0 (10.2)		10 /	1.00 1	A TN 1 4 5 7
uCB Pharma409201647.6 (11.4)Double blindand 22 400mg wice weekly48 weeks 400mgCertolizumabPegol twice weeklyCelgene Corp.504201650.4 (11.66)Double blind30 mg twice daily5 years dailyApremilastNovartis Eli lilly& company6062016552 2017Double blind150 mg twice daily24 weeks textizumabSecukinumab takinabRheumatoi d arthritisAbbott619 802011402 46.9 (16.22)Double blind Double blind120 weeks textizumab40 mg / week daily takinabAdalimumab daily dailyRheumatoi d arthritisAbbott619 80201246.9 (16.22) 46.9 (16.22)Double blind Double blind28 days textice daily50 mg once dailyINCB018424 daily 435+MethotrexateMitsubishi Pharma Corp.334201254.0 (13.15)Double blind to use kind12 weeks textice daily100 mg twice dailyMP- daily dailyUlcerative colitisCentocor Inc.60201313.4 (3.10)Open label54 weeks textice tweeks5 mg/kg every 12 weeksInfliximab weeksUlcerative colitisValeant Ph. Int.Inc.410201442.7 (12.8)Double blind8 weeks textice9 mg every g udesonide-MMX day+2 Asacol		Novartis	42	2015	47.0 (10.2)	Double blind		169 days	AIN457
PharmatwiceCelgene Corp.504201650.4 (11.66)Double blind30 mg twice daily5 years twice dailyApremilastNovartis Eli lilly& company6062016552 2017Double blind150 mg 24 weeks24 weeks secukinumabSecukinumabRheumatoi d arthritisAbbott619 802011402 2012Double blind160 mg 12 weeks24 weeks 40 mg / weekAdalimumab datinumabRheumatoi d arthritisAbbott619 802011402 2012Double blind12 weeks 46.9 (16.22)600 mg on day 1,15.43Canakinumab day 1,15.43Incyte Corp.50201554.9 (11.23) 54.9 (11.23)Double blind28 days50 mg onc dailyINCB018424 dailyAbbott334201254.0 (13.15) 54.9 (11.23)Double blind52 weeks40 mg SC/ weekAdalimumab weekMitsubishi Pharma Corp.93201427Double blind12 weeks100 mg twice weekMP- dailyUlcerative colitisCentocor Inc.60201313.4 (3.10)Open label54 weeks5 mg/kg every 12 weeksInfliximab every 12 weeksValeant Ph. Int,Inc.410201443.6 (13.6)Double blind8 weeks9 mg every mg every dailyBudesonide-MMX day+3 acolValeant Ph. Int,Inc.489201442.7 (12.8)Double blind8 weeks9 mg every mg everyBudeson	arunnus								
Celgene Corp.504201650.4 (11.66)Double blindDouble blind 30 mg twice daily5 years yearsApremilastNovartis Eli lilly& d arthritis6062016552 49.52 (11.87)Double blind Double blind150 mg 160 mg 24 weeks24 weeks Secukinumab Ice valueSecukinumab Ice valueRheumatoi d arthritisAbbott Novartis619 802011 201240.22 46.9 (16.22)Double blind Double blind150 mg 160 mg 24 weeks24 weeks Secukinumab Ice valueAdalimumab Canakinumab day 1,15,43Rheumatoi d arthritisAbbott Novartis619 80201254.9 (11.23) 54.9 (11.23)Double blind Double blind28 days 20 weeks50 mg once dailyINCB018424 dailyAbbott Tanabe Pharma Corp.334 Loc partice201254.0 (13.15) FanabeDouble blind Pharma Corp.52 weeks mg SC/ AdalimumabMP- dailyUlcerative colitisCentocor Inc.60 Loc partice2013 Loc partice13.4 (3.10) Loc particeOpen label Pharma Corp.54 weeks5 mg/kg every 12 weeksInfliximab every 12 weeksValeant Ph. Int,Inc.410 Valeant Ph. H, Int,Inc.2014 Loc partice43.6 (13.6) Lou particeDouble blind Pouble blind8 weeks9 mg every P mg every Budesonide-MMX day+3 EntocortBudesonide-MMX day+2 Asacol		UCB	409	2016	47.6 (11.4)	Double blind		48 weeks	CertolizumabPegol
Celgene Corp.504201650.4 (11.66)Double blind30 mg twice daily5 years yearsApremilastNovartis Eli lilly& d arthritis6062016552 2017Double blind150 mg 100uble blind24 weeks of 2 SC injectionsSecukinumab LekizumabRheumatoi d arthritisAbbott619 Novartis2011402 2012Double blind52 weeks day 1,15,4340 mg / week day 1,15,43Adalimumab day 1,15,43Incyte Corp.50 Abbott201554.9 (11.23) 54.9 (11.23)Double blind28 days days50 mg once dailyINCB018424 dailyMitsubishi Pharma Corp.93 Locp.201427 Locp.Double blind12 weeks100 mg twice weekMP- dailyUlcerative colitisCentocor Inc.60 Locp.201313.4 (3.10)Open label54 weeks5 mg/kg every 12 weeksInfliximab every 12 weeksValeant Ph. Int,Inc.410 Locp.201442.7 (12.8)Double blind8 weeks9 mg every mg everyBudesonide-MMX day+3 Ascol		Pharma							
twice dailyNovartis Eli lilly& company6062016552 49.52 (11.87)Double blind150 mg 160 mg 24 weeks24 weeks Secukinumab Iso mg 24 weeksSecukinumab IzekizumabRheumatoi d arthritisAbbott619 Novartis2011402 46.9 (16.22)Double blind52 weeks Double blind40 mg / week 600 mg on day 1,15,43Adalimumab day 1,15,43Incyte Corp.50 Abbott201554.9 (11.23) 54.9 (11.23)Double blind28 days week50 mg once aday 1,15,43INCB018424 dailyAbbott334 Corp.201254.0 (13.15) Famabe Corp.Double blind52 weeks week40 mg SC/ weekAdalimumab day 1,15,43Ulcerative colitisCentocor Inc.60201313.4 (3.10)Open label54 weeks5 mg/kg every 12Infliximab every 12Valeant Ph. Int,Inc.410201443.6 (13.6)Double blind8 weeks9 mg every everyBudesonide-MMX day+3 EntocortValeant Ph. Int,Inc.489201442.7 (12.8)Double blind8 weeks9 mg every everyBudesonide-MMX day+2 Asacol			504	2016	50 4 (11 (0)		-	F	A 11 (
Novartis Eli illy& company606 20162016 2017552 49.52 (11.87)Double blind Double blind150 mg 160 mg 24 weeks24 weeks SecukinumabSecukinumab ItekizumabRheumatoi d arthritisAbbott Novartis619 802011 2012402 46.9 (16.22)Double blind Double blind150 mg 16.22)24 weeks injections40 mg / week dainumabAdalimumab CanakinumabRheumatoi d arthritisAbbott Novartis619 802011 201246.9 (16.22) 46.9 (16.22)Double blind Double blind12 weeks 28 days40 mg / week 600 mg on day 1,15,43Adalimumab Canakinumab day 1,15,43Incyte Corp. Tarabe Pharma Corp.50 20132012 24.0 (13.15)52 weeks Double blind40 mg SC/ 28 daysAdalimumab 28 daysMCB018424 dailyUlcerative colitis60 Inc.2013 201413.4 (3.10)Open label12 weeks 24 weeks100 mg twice weekMP- 435+MethotrexateUlcerative colitis60 Inc.2013 13.4 (3.10)13.4 (3.10)Open label54 weeks 24 weeks5 mg/kg 2 mg every 24 weeksInfliximab every 12 weeksValeant Ph. Int,Inc.410 Valeant Ph. H201442.7 (12.8)Double blind Double blind8 weeks 8 mg every 9 mg every 9 mg every Budesonide-MMX day+2 Asacol8 weeks 9 mg everyBudesonide-MMX day+2 Asacol			504	2016	50.4 (11.66)	Double blind		5 years	Apremilast
Novartis Eli illy& company606 20172016 49.52 (11.87)552 49.52 (11.87)Double blind Double blind150 ng ng 24 weeks24 weeks Secukinumab Itom 24 weeksSecukinumab IxekizumabRheumatoi d arthritisAbbott Novartis619 802011 2012402 46.9 (16.22)Double blind Double blind52 weeks 40 mg / week40 and / week Adalimumab day 1,15,43Adalimumab Canakinumab day 1,15,43Incyte Corp.50201554.9 (11.23) 54.9 (11.23)Double blind28 days a 50 mg once daily50 mg once dailyINCB018424 dailyAbbott334201254.0 (13.15) 2014Double blind52 weeks40 mg SC/ weekAdalimumab day 1,15,43Misubishi Pharma Corp.93201427Double blind12 weeks100 mg twice weekMP- dailyUlcerative colitisCentocor Inc.60201313.4 (3.10)Open label54 weeks5 mg/kg every 12 weeksInfliximab every 12 weeksValeant Ph. Int,Inc.410201443.6 (13.6)Double blind8 weeks9 mg every g mg everyBudesonide-MMX day+3 EntocortValeant Ph. Int,Inc.489201442.7 (12.8)Double blind8 weeks9 mg every g mg everyBudesonide-MMX day+2 Asacol		corp.							
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			606	2016	552	Double blind		24 weeks	Secukinumab
Rheumatoi d arthritisAbbott Novartis619 802011 2012402 46.9 (16.22)Double blind Double blind52 weeks 12 weeks40 mg / week 600 mg on day 1,15,43Adalimumab Canakinumab day 1,15,43Incyte Corp.50201554.9 (11.23)Double blind28 days50 mg once dailyINCB018424Abbott334201254.0 (13.15)Double blind52 weeks40 mg SC/ dailyAdalimumab weekMitsubishi Pharma Corp.93201427Double blind12 weeks100 mg twice everyMP- dailyUlcerative colitisCentocor Inc.60201313.4 (3.10)Open label54 weeks5 mg/kg every 12 weeksInfliximabValeant Ph. Int,Inc.410201442.7 (12.8)Double blind8 weeks9 mg every mg everyBudesonide-MMX day+2 Asacol		-	417	2017	49.52 (11.87)	Double blind		24 weeks	Ixekizumab
Rheumatoi d arthritisAbbott Novartis619 802011 2012402 46.9 (16.22)Double blind Double blind52 weeks to use k40 mg / week 600 mg on day 1,15,43Adalimumab CanakinumabIncyte Corp.50201554.9 (11.23)Double blind28 days50 mg once dailyINCB018424 dailyAbbott334201254.0 (13.15)Double blind52 weeks40 mg SC/ weekAdalimumabMitsubishi Tanabe Pharma Corp.93201427Double blind12 weeks100 mg twice dailyMP- 435+MethotrexateUlcerative colitisCentocor Inc.60201313.4 (3.10)Open label54 weeks5 mg/kg every 12 weeksInfliximabValeant Ph. Int,Inc.410201443.6 (13.6)Double blind8 weeks9 mg every day+3Budesonide-MMX day+2 Asacol		company							
d arthritis Novartis 80 2012 46.9 (16.22) Double blind 12 weeks 600 mg on day 1,15,43 Incyte Corp. 50 2015 54.9 (11.23) Double blind 28 days 50 mg once daily Abbott 334 2012 54.0 (13.15) Double blind 52 weeks 40 mg SC/ Adalimumab Mitsubishi 93 2014 27 Double blind 12 weeks 100 mg twice MP- Tanabe Pharma Corp. Ulcerative colitis Inc. Valeant Ph. 410 2014 43.6 (13.6) Double blind 54 weeks 9 mg every 2 Valeant Ph. 489 2014 42.7 (12.8) Double blind 8 weeks 9 mg every Budesonide-MMX Int,Inc.	Rheumatoi	Abbott	619	2011	402	Double blind		40 mg / week	Adalimumah
Incyte Corp.50201554.9 (11.23)Double blind28 days50 mg once dailyINCB018424 dailyAbbott334201254.0 (13.15)Double blind52 weeks40 mg SC/ Adalimumab weekMitsubishi93201427Double blind12 weeks100 mg twice 									
Abbott334201254.0 (13.15)Double blind52 weeks40 mg SC/ weekAdalimumab weekMitsubishi93201427Double blind12 weeks100 mg twiceMP-Tanabe Pharma Corp.7Double blind12 weeks100 mg twiceMP-Ulcerative colitisCentocor60201313.4 (3.10)Open label54 weeks5 mg/kgInfliximabValeant Ph. Int,Inc.410201443.6 (13.6)Double blind8 weeks9 mg every day+3Budesonide-MMXValeant Ph. Int,Inc.489201442.7 (12.8)Double blind8 weeks9 mg every day+2 AsacolBudesonide-MMX					. ,				
Abbott334201254.0 (13.15)Double blind52 weeks40 mg SC/ weekAdalimumabMitsubishi93201427Double blind12 weeks100 mg twiceMP-Tanabe Pharma Corp.7Double blind12 weeks100 mg twiceMP-Ulcerative colitisCentocor60201313.4 (3.10)Open label54 weeks5 mg/kg every 12 weeksInfliximabValeant Ph. Int,Inc.410201443.6 (13.6)Double blind8 weeks9 mg every day+3 EntocortBudesonide-MMX day+2 Asacol		Incyte Corp.	50	2015	54.9 (11.23)	Double blind	28 days		INCB018424
Mitsubishi Tanabe Pharma Corp.93201427Double blind12 weeks100 mg twice dailyMP- 435+MethotrexateUlcerative colitisCentocor Inc.60201313.4 (3.10)Open label54 weeks5 mg/kg every 12InfliximabValeant Ph. Int,Inc.410201443.6 (13.6)Double blind8 weeks9mg every day+3Budesonide-MMXValeant Ph. Int,Inc.489201442.7 (12.8)Double blind8 weeks9 mg every day+2 AsacolBudesonide-MMX		Abbott	224	2012	540(1215)	Double blind	50 maalaa		Adolimumoh
Mitsubishi Tanabe Pharma Corp.93201427Double blind12 weeks100 mg twice dailyMP- 435+MethotrexateUlcerative colitisCentocor Inc.60201313.4 (3.10)Open label54 weeks5 mg/kg every 12InfliximabValeant Ph. Int,Inc.410201443.6 (13.6)Double blind8 weeks9mg every day+3Budesonide-MMXValeant Ph. Int,Inc.489201442.7 (12.8)Double blind8 weeks9 mg every day+2 AsacolBudesonide-MMX		Abbou	554	2012	54.0 (15.15)	Double blilld	JZ WEEKS		Auaimumao
Tanabe Pharma Corp.daily435+MethotrexateUlcerative colitisCentocor60201313.4 (3.10)Open label54 weeks5 mg/kg every 12InfliximabUlcerative colitisCentocor60201313.4 (3.10)Open label54 weeks5 mg/kg every 12InfliximabValeant Ph. Int,Inc.410201443.6 (13.6)Double blind8 weeks9 mg every day+3Budesonide-MMX day+3Valeant Ph. Int,Inc.489201442.7 (12.8)Double blind8 weeks9 mg every day+2 AsacolBudesonide-MMX		Mitsubishi	93	2014	27	Double blind	12 weeks		MP-
Corp. Ulcerative colitisCentocor Inc.60201313.4 (3.10)Open label54 weeks5 mg/kg every 12InfliximabValeant Ph. Int,Inc.410201443.6 (13.6)Double blind8 weeks9mg every day+3Budesonide-MMX day+3Valeant Ph. Int,Inc.489201442.7 (12.8)Double blind8 weeks9 mg every day+2 AsacolBudesonide-MMX		Tanabe						-	435+Methotrexate
Ulcerative colitisCentocor Inc.60201313.4 (3.10)Open label54 weeks5 mg/kg every 12 weeksInfliximabValeant Ph.410201443.6 (13.6)Double blind8 weeks9 mg every day+3 EntocortBudesonide-MMX day+3 EntocortValeant Ph.489201442.7 (12.8)Double blind8 weeks9 mg every day+2 AsacolBudesonide-MMX									
colitis Inc. Valeant Ph. 410 2014 43.6 (13.6) Double blind 8 weeks 9mg every Budesonide-MMX Int,Inc. Valeant Ph. 489 2014 42.7 (12.8) Double blind 8 weeks 9 mg every Int,Inc. Ualeant Ph. 489 2014 42.7 (12.8) Double blind 8 weeks 9 mg every Int,Inc.	Illogrativo	-	60	2012	12 4 (2 10)	Onan labal	54 weeks	5 mg/kg	Inflivingh
Valeant Ph. 410 2014 43.6 (13.6) Double blind 8 weeks 9mg every Budesonide-MMX Int,Inc. Entocort Valeant Ph. 489 2014 42.7 (12.8) Double blind 8 weeks 9 mg every Budesonide-MMX Int,Inc. Budesonide-MMX day+2 Asacol			00	2015	15.4 (5.10)	Open laber	J4 weeks	0 0	mmximao
Int,Inc. Valeant Ph. 489 2014 42.7 (12.8) Double blind 8 weeks 9 mg every Budesonide-MMX Int,Inc. day+3 Entocort day+2 Asacol	contrib	inc.							
Valeant Ph. 489 2014 42.7 (12.8) Double blind 8 weeks 9 mg every Budesonide-MMX Int,Inc. day+2 Asacol		Valeant Ph.	410	2014	43.6 (13.6)	Double blind	8 weeks		Budesonide-MMX
Valeant Ph.489201442.7 (12.8)Double blind8 weeks9 mg every day+2 AsacolBudesonide-MMX day+2 Asacol		Int,Inc.						-	
Int,Inc. day+2 Asacol		Valeant Dh	180	2014	127(128)	Double blind	8 waaka		Budesonida MMV
			409	2014	42.7 (12.0)	Double blilld	o weeks		Dudesoniue-IVIIVIA
Pfizer 195 2013 110 Double blind 8 weeks 15 mg twice CP-690,550		Pfizer	195	2013	110	Double blind	8 weeks	15 mg twice	CP-690,550
daily								-	

E-ISSN: 0975-8232; P-ISSN: 2320-5148

AbbVie	273	2014	42.7 (14.38)	Double blind	221 weeks	160 mg on day 1,80 mg at week 2, 40 mg /week	Adalimumab
GW Research Ltd	60	2015	43.77(13.90)	Double blind	10 weeks	from 4 to 50 1-5 capsules twice daily	GWP42003

Statistical Analysis: Meta-analysis was performed for assessing between the treatment group and control group. Odds ratio and confidence interval were graphically represented with the help of forest plots, while funnel plots deputed publication biases. Radial and QQ normal plots were used to represent numerical values such as angle and for showing the normal distribution of studies.

Heterogeneity was calculated using χ^2 and I^2 index statistics, the effect size measurement using odds ratio, and the confidence interval, odds ratio, and p-value were calculated for individual study. R software was used for statistical analysis and metafor package ⁴⁵ was used to calculate the estimated result. With the help of the studies collected, biological therapy was compared against placebo treatment.

It was seen that the result favors experiments showing tuberculosis as a side effect in the biologics using the metafor package. The tool makes use of various parameters, which are described as follows. Effect size, which is a computable determination of robustness of occurrence. Escalc function was used to calculate the effect size or outcome measure. The result was vi (observed value of the effect size or outcome measure in the studies) and vi (corresponding sampling variance) for each disease. Odds ratio (OR) was calculated with the help of Mantel-Haenszel Method, which is a process that creates an evaluation of an association between an exposure and an outcome after modifying for or taking stagger into account. The formula for OR can be represented as

$$Or (MH) = a \times d / t / c \times b / t$$

In which a and c are the number of events and total of experiments, b and d are the number of events and total of control, t is the total of all study. 95% confidence interval was used for this analysis, where confidence interval (CI) is a type of interval approximation of a population. If an equivalent hypothesis test is performed, the confidence level accompanies the significance level, i.e. a 95% confidence interval indicates a significance level of 0.05. P-value is the probability of acquiring a result uniform to or maximum than what is actually noticed when the null hypothesis is true. Z-value (absolute value) shows the distance between the raw score and the population means in standard deviation units. μ and σ are the mean and standard deviation of the population, respectively.

These parameters were calculated for studies of each diseases separately. *forest()* function was used to create the forest plot in R. Forest plot is the graphical representation of a meta-analysis which is generally escorted by a table with a list of authors and year of the studies which are taken in doing the meta-analysis.

A funnel plot, a scatter plot of treatment effect against a measure of study precision, was used to check biasness and systematic heterogeneity. When a symmetrical funnel shaped appear from a courteous data set, it is accounted that there are no publication biases. Funnel function was used to see the biasness in R. Heterogeneity was present in the selected studies, so a fixed effect model was used. Besides these, radial plots, which is a method to evaluate the stability of discovered result that have varying precisions was used to plot inverse of standard errors on horizontal axis against the individual discovered result systemized by their respective standard errors on vertical axis (i.e., $vi=\sqrt{vi}$ in fixed effect model ⁴². Q-Q normal plots were also generated, which display the theoretical quantiles of a normal distribution on the horizontal axis against the observed quantiles of the externally systemized residuals on the vertical axis 42.

RESULTS:

Ankylosing Spondylitis: Biologic therapy comparison was done with placebo therapy. It was seen that the result favors the experiment as compared to placebo [OR=0.8962, 95%CI=0.83-

0.97, P-value>0.005] **Fig. 1A**. heterogeneity was calculated $[\chi^2=21.53, I^2=64.28\%]$. No such publication bias is seen **Fig. 1B**. Radial plot plots

the value of numeric as angle of radians **Fig. 1C.** Also, the QQ plot shows that the data is normally distributed **Fig.1D.**



FIG. 1: (A) FOREST PLOT, (B) FUNNEL PLOT, (C) RADIAL PLOT AND (D) QQ PLOT FOR ANKYLOSING SPONDYLITIS

Crohn's disease: Biologic therapy comparison was done with placebo therapy. The result was seen to favor the experiment as compared to the placebo [OR=0.82, 95%CI=0.76-0.89, P-value <0.0001]. **Fig. 2A**. Heterogeneity was calculated [χ^2 =122.29,

 I^2 =96.71%]. No such publication bias is seen **Fig. 2B.** Radial plot plots the value of numeric as angle of radians **Fig. 2C**. Also, the QQ plot shows that the data is normally distributed **Fig. 2D**.



FIG. 2: (A) FOREST PLOT, (B) FUNNEL PLOT, (C) RADIAL PLOT AND (D) QQ PLOTFOR ANKYLOSING SPONDYLITIS CROHN'S DISEASE

Psoriasis: Biologic therapy comparison was done with placebo therapy. It was seen that the result favors experiment as compared to placebo [OR=0.72, 95% CI=0.65-0.79, P-value<0.0001] **Fig. 3A**. Heterogeneity was calculated [χ^2 =21.68,

 I^2 =70.04%]. No such publication bias is seen **Fig. 3B**. Radial plot plots the value of numeric as angle of radians **Fig. 3C**. Also, the QQ plot shows that the data is normally distributed **Fig. 3D**.



FIG. 3: (A) FOREST PLOT, (B) FUNNEL PLOT, (C) RADIAL PLOT AND (D) QQ PLOT FOR ANKYLOSING SPONDYLITIS PSORIASIS

Psoriatic Arthritis: Biologic therapy comparison was done with placebo therapy. It was seen that the result favors the experiment as compared to placebo [OR=0.77, 95% CI=0.68-0.87, P-value<0.0001] **Fig. 4A**. Heterogeneity was

calculated $[\chi^2=3.10, I^2=0\%]$. No such publication bias is seen **Fig. 4B**. Radial plot plots the value of numeric as angle of radians **Fig. 4C**. Also, the QQ plot shows that the data is normally distributed **Fig. 4D**.



FIG. 4: (A) FOREST PLOT, (B) FUNNEL PLOT, (C) RADIAL PLOT AND (D) QQ PLOT FOR ANKYLOSING SPONDYLITIS PSORIATIC ARTHRITIS

Rheumatoid Arthritis: Biologic therapy comparison was done with placebo therapy. It was seen that the result favors the experiment as compared to placebo [OR=0.65, 95% CI=0.53-0.79, P-value<0.0001] **Fig. 5A**. Heterogeneity was

calculated $[\chi^2=11.29, I^2=37.61\%]$. No such publication bias is seen **Fig. 5B**. Radial plot plots the value of numeric as angle of radians **Fig. 5C**. Also, the QQ plot shows that the data is normally distributed **Fig. 5D**.



FIG. 5: (A) FOREST PLOT, (B) FUNNEL PLOT, (C) RADIAL PLOT AND (D) QQ PLOT FOR RHEUMATOID ARTHRITIS

Ulcerative Colitis: Biologic therapy comparison was done with placebo therapy. It was seen that the result favors experiment as compared to placebo [OR=0.45, 95% CI=0.36-0.56, P-value<0.0001] **Fig. 6A**. Heterogeneity was calculated [χ^2 =12.05,

 $I^2=0\%$]. No such publication bias is seen **Fig. 6B**. Radial plot plots the value of numeric as angle of radians **Fig. 6C**. Also, the QQ plot shows that the data is normally distributed **Fig. 6D**.



FIG. 6: (A) FOREST PLOT, (B) FUNNEL PLOT, (C) RADIAL PLOT AND (D) QQ PLOT FOR ULCERATIVE COLITIS

CONCLUSION: A meta-analysis of biological therapy *vs.* placebo therapy is done for disease like ankylosing spondylitis, Crohn's disease, psoriasis, rheumatoid arthritis, psoriatic arthritis, ulcerative colitis with different study group of each disease to see the side effect caused by the biologics of these

diseases. After meta-analysis, it can be seen that the result follows the experiment which can be concluded that the biologics of each disease gives side effect of tuberculosis. End-point measures for each diseases is estimated. The study is grouped as biologic therapy and placebo therapy. A comparison between both groups gave a statistically significant result. The P-value for each endpoint measures ankylosing spondylitis (P>0.005), Crohn's disease (P<0.0001), psoriasis (P<0.0001), psoriatic arthritis (P<0.0001), rheumatoid arthritis (P<0.0001), ulcerative colitis (P<0.0001) which is less than 0.05.

Publication bias was also checked with the help of a funnel plot. No such publication bias was found in each disease. This meta-analysis might contain many limitations due to search strategy applied, inclusion and exclusion criteria of studies and publication bias. Different protocols were developed to extract data from studies and analyze those data. But a vigorous strategy is applied for meta-analysis and it will help in fortune for clinical trial in biologics giving tuberculosis as side effects.

The prominence of this study was to find the side effects that can be caused by the biologics of diseases like, ankylosing spondylitis, Crohn's disease, psoriasis, rheumatoid arthritis, psoriatic arthritis, ulcerative colitis. Finally, a meta-analysis of a clinical trial is applied, showing that the biologics have side effects. Therefore, it can be concluded that the biologics of diseases like ankylosing spondylitis, Crohn's disease, psoriasis, rheumatoid arthritis, psoriatic arthritis, ulcerative colitis give tuberculosis as side effects.

ACKNOWLEDGEMENT: The authors acknowledge the Department of Bioinformatics & Applied Sciences, Indian Institute of Information Technology, Allahabad, for providing a computing facility. The authors thank Prof. S.P. Mishra for sharing his expertise upon consultation.

CONFLICTS OF INTEREST: The authors have no conflict of interest.

REFERENCES:

- 1. Pham JV, Yilma MA, Feliz A, Majid MT, Maffetone N and Walker JR: A Review of the Microbial Production of Bioactive Natural Products and Biologics. Frontiers in Microbiology 2019; 10: 1404.
- Makurvet FD: Biologics vs. small molecules: Drug costs and patient access. Medicine in Drug Discovery 2021; 9: 100075.
- 3. Castelli MS, McGonigle P and Hornby PJ: The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacology Research & Perspectives 2019; 7(6): 00535.

- Cantini F, Niccoli L, Capone A, Petrone L and Goletti D: Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-antitumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. Expert Opinion on Drug Safety 2019; 18(5): 415-25.
- 5. Zou A, Chen Y, Shi N and Ye Y: Risk of herpes zoster associated with biological therapies for psoriasis and psoriatic arthritis: A systematic review and meta-analysis. Medicine 2021; 100(40): 27368.
- Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis. Available from: https://ClinicalTrials.gov/show/NCT00809159.
- 7. EValuation of HumIRA® in Patients with Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries. Available from: https://ClinicalTrials.gov/show/NCT01078402.
- Extension Study Evaluating Etanercept in Ankylosing Spondylitis. Available from: https://ClinicalTrials.gov/show/NCT00410046.
- 9. Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects with Active Ankylosing Spondylitis. Available from: https://ClinicalTrials.gov/show/NCT00085644.
- 10. The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012). Available from: https://ClinicalTrials.gov/show/NCT01668004.
- 11. Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis. Available from: https://ClinicalTrials.gov/show/NCT00247962.
- 12. Study of Apremilast to Treat Subjects with Active Ankylosing Spondylitis. Available from: https://ClinicalTrials.gov/show/NCT01583374.
- 13. A Study of the Safety and Efficacy of Golimumab in Subjects with Active Ankylosing Spondylitis. Available from: https://ClinicalTrials.gov/show/NCT00265083.
- 14. Certolizumab in Crohn's Disease Patients with Loss of Response or Intolerance to Infliximab. Available from: https://ClinicalTrials.gov/show/NCT00308581.
- 15. Efficacy and Safety of Adalimumab in Pediatric Subjects with Moderate to Severe Crohn's Disease. Available from: https://ClinicalTrials.gov/show/NCT00409682.
- 16. Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease. Available from: https://ClinicalTrials.gov/show/NCT00329550.
- 17. A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence. Available from: https://ClinicalTrials.gov/show/NCT01190839.
- 18. Special Investigation in Patients with Crohn's Disease (All Patients Investigation). Available from: https://ClinicalTrials.gov/show/NCT01298648.
- 19. Adalimumab in Adult Japanese Subjects with Psoriasis. Available from: https://ClinicalTrials.gov/show/NCT00647400.
- 20. Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis. Available from: https://ClinicalTrials.gov/show/NCT00678210.
- 21. Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis. Available from: https://ClinicalTrials.gov/show/NCT00581100.

- 22. Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adalimumab. Available from: https://ClinicalTrials.gov/show/NCT01077128.
- 23. Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept. Available from: https://ClinicalTrials.gov/show/NCT00992394.
- 24. Study Evaluating Etanercept in the Treatment of Subjects with Psoriasis. Available from: https://ClinicalTrials.gov/show/NCT00195507.
- 25. Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients with Moderate to Severe Plaque Psoriasis. Available from: https://ClinicalTrials.gov/show/NCT01232283.
- 26. Certolizumab Pegol in Subjects with Adult Onset Active and Progressive Psoriatic Arthritis. Available from: https://ClinicalTrials.gov/show/NCT01087788.
- 27. An Effectiveness and Safety Study of CNTO 1275 in Patients with Active Psoriatic Arthritis. Available from: https://ClinicalTrials.gov/show/NCT00267956.
- 28. Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis. Available from: https://ClinicalTrials.gov/show/NCT01172938.
- 29. Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA). Available from: https://ClinicalTrials.gov/show/NCT01392326.
- 30. Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis. Available from: https://ClinicalTrials.gov/show/NCT00809614.
- 31. Safety and Efficacy of Abatacept versus Placebo in Participants with Psoriatic Arthritis. Available from: https://ClinicalTrials.gov/show/NCT00534313.
- 32. Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis. Available from: https://ClinicalTrials.gov/show/NCT00245960.
- A Study of Ixekizumab in Participants with Active Psoriatic Arthritis. Available from: https://ClinicalTrials.gov/show/NCT01695239.
- 34. Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With

Methotrexate. Available from: https://ClinicalTrials.gov/show/NCT00195702.

- 35. Efficacy and Safety Study of MP-435 in Combination with Methotrexate (MTX) in Patients with Rheumatoid Arthritis. Available from: https://ClinicalTrials.gov/show/NCT01143337.
- Safety and Efficacy of ACZ885 in Adult Patients with Established Rheumatoid Arthritis. Available from: https://ClinicalTrials.gov/show/NCT00504595.
- 37. A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis. Available from: https://ClinicalTrials.gov/show/NCT00550043.
- A Study of Adalimumab in Japanese Subjects with Rheumatoid Arthritis. Available from: https://ClinicalTrials.gov/show/NCT00870467.
- (CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMXTM) 6 mg and 9 mg in Patients with Ulcerative Colitis. Available from: https://ClinicalTrials.gov/show/NCT00679432.
- (CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX[™]) 6 mg and 9 mg in Patients with Ulcerative Colitis. Available from: https://ClinicalTrials.gov/show/NCT00679380.
- 41. A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis (GWID10160). Available from: https://ClinicalTrials.gov/show/NCT01562314.
- 42. A Study of Adalimumab in Japanese Subjects with Moderately to Severely Active Ulcerative Colitis. Availablefrom:https://ClinicalTrials.gov/show/NCT00853 099.
- 43. A Study of the Safety and Efficacy of Infliximab (REMICADE) in Pediatric Patients with Moderately to SeverelyActive Ulcerative Colitis. Available from: https://ClinicalTrials.gov/show/NCT00336492.
- 44. A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients with Moderate and Severe Ulcerative Colitis. Available from: https://ClinicalTrials.gov/show/NCT00787202.
- 45. Viechtbauer W: Conducting meta-analyses in R with the metafor package. J of Statist Software 2010; 36(3): 1-48.

How to cite this article:

Nayak A, Semwal R, Varadwaj PK and Aier I: Infections associated with biologic therapy: a clinical meta- analysis study. Int J Pharm Sci & Res 2023; 14(5): 2532-40. doi: 10.13040/IJPSR.0975-8232.14(5).2532-40.

All © 2023 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to Android OS based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)